Navigation Links
Halozyme Therapeutics Reports First Quarter 2011 Financial Results
Date:5/6/2011

ts are also identified through use of the words "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a result of several factors, including regulatory approval requirements and competitive conditions. These and other factors that may result in differences are discussed in greater detail in the company's reports on Forms 10-K, 10-Q, and other filings with the Securities and Exchange Commission.

Halozyme Contact
Robert H. Uhl
Senior Director, Investor Relations
(858) 704-8264
ruhl@halozyme.comHalozyme Therapeutics, Inc.Condensed Consolidated Statements of OperationsQuarters Ended March 31,20112010(unaudited)(unaudited)REVENUES:Product sales

$
5,449$
397,810Revenues under collaborative agreements

7,378,4453,043,921Total revenues

7,543,8943,441,731OPERATING EXPENSES:Cost of product sales

11,7175,660Research and development

13,785,79711,467,204Selling, general and administrative

3,405,9663,757,013Total operating expenses

17,203,48015,229,877OPERATING LOSS

(9,659,586)(11,788,146)Interest and other income, net

23,869669NET LOSS

$
(9,635,717)$  (11,787,477)Basic and diluted net loss per share

$
(0.10)$
(0.13)Shares used in computing basic and dilutednet loss per share

100,927,40291,610,830Halozyme Therapeutics, Inc.Condensed Consolidated Balance SheetsMarch 31, December 31,20112010(unaudited)ASSETS Current assets:Cash and cash equivalents

$
73,829,299$
83,255,848Accounts receivable

1,731,3252,328,268Inventory.

248,474193,422Prepaid expenses and other assets.

3,382,9933,720,896Total current assets

79,19
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Halozymes Ultrafast Insulin Generates Faster-In and Faster-Out Profile for Type 1 Diabetes Patients Using Insulin Pumps
2. Halozyme Announces Roche Doses First Patient in Phase 3 Clinical Trial With Subcutaneous MabThera® (rituximab)
3. Halozyme Therapeutics Reports Third Quarter 2010 Financial Results
4. Halozyme Receives $5.5 Million Payment From Baxter
5. Halozyme Therapeutics Reports 2008 Third Quarter Financial Results
6. Halozyme Therapeutics Begins Phase 2 Clinical Trial of Insulin With rHuPH20 in Type 1 Diabetic Patients
7. Halozyme Therapeutics Announces Conference Call on November 6 to Review Third Quarter Results
8. Halozyme Therapeutics to Present at Upcoming Investor Conferences
9. Halozyme Therapeutics to Host Research Day for Investors and Analysts
10. Halozyme Therapeutics Appoints Head of Endocrinology Clinical Development
11. Halozyme Therapeutics to Present at Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... (PRWEB) December 19, 2014 Bioject ... developer and manufacturer of needle-free injection technology, today ... with Immunomic Therapeutics, Inc. (“ITI”) for ITI to ... with its LAMP™ vaccine platform. , In ... exclusive Worldwide license to the Biojector®-2000 that triggers ...
(Date:12/19/2014)... 19, 2014 BioPlus Specialty Pharmacy ... announces the promotion of Nick Maroulis, Pharm.D. to the ... Services. , In this position, Dr. Maroulis will ... managing the directors of our multi-site pharmacies as the ... 1997 and during that time he has served in ...
(Date:12/19/2014)... , Dec. 19, 2014  Roche (SIX: RO, ROG; ... Technologies, Inc. (Bina), a privately held company based ... USA. Bina provides a big data platform for ... (NGS) data. Bina,s proprietary on-market Genomic Management Solution, ... researchers to perform fast and scalable analyses to ...
(Date:12/19/2014)... Dec. 19, 2014 Decision Resources Group finds ... at a 12 percent compound annual growth rate through ... aging population and the increasing adoption of dental implants. ... will also spur demand for dental biomaterials because ... and periodontal treatments. Other key findings from ...
Breaking Biology Technology:Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2Roche acquires Bina Technologies and enters the genomic informatics market 2Roche acquires Bina Technologies and enters the genomic informatics market 3Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 2Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 3
... Jan. 3 Escalon Medical Corp.,(Nasdaq Capital Market: ... 510(k) clearance from the U.S. Food and Drug,Administration ... The MASTER-VU(TM) System consists of a B-scan probe ... (via a USB cable,connection) using Sonomed,s proprietary software, ...
... Jan. 3 Cinpathogen, through its,partnership in the ... clinical diagnostic technology consulting,services to Shanghai area hospitals. ... the,Shanghai Health Study, the Center has diagnosed and ... in collaboration with area,hospitals and colleagues at Fudan ...
... KENILWORTH, N.J., Jan. 2 Schering-Plough,Corporation (NYSE: ... and Drug,Administration (FDA) has assigned priority review status ... Sugammadex is specifically designed to reverse the ... States as ZEMURON(R) (rocuronium,bromide) and vecuronium bromide. Muscle ...
Cached Biology Technology:Escalon(R) Announces FDA 510(k) Clearance for Sonomed MASTER-VU(TM) B-Scan System 2Escalon(R) Announces FDA 510(k) Clearance for Sonomed MASTER-VU(TM) B-Scan System 3Cinpathogen Provides Clinical Diagnostic Consulting Services to Shanghai Area Hospitals 2Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA 2Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA 3Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA 4
(Date:12/19/2014)... , Dec. 18, 2014 Research and ... the addition of the "iPhone 5S Fingerprint ... Report" report to their offering. ... the acquisition of AuthenTec in July 2012, Apple ... 5S. It is currently the only device of ...
(Date:12/19/2014)... , Dec. 18, 2014  23andMe, Inc., the ... a study that pinpoints fine-scale differences in genetic ancestry ... . Since immigrants first arrived more ... States has served as a meeting place ... American history and the ongoing mixing of peoples with ...
(Date:12/17/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/s6qzt5/samsung_galaxy_s5 ) ... Galaxy S5 - Home Button Synaptics Fingerprint Sensor ... http://photos.prnewswire.com/prnh/20130307/600769 ... the iPhone 5S, Samsung introduces for the first ... The Galaxy S5 home button presents an ...
Breaking Biology News(10 mins):iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire - Technology Report 223andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2
... New York University biologists have uncovered how the innate ... neurons. The findings, published as the cover study in ... neurons fight the virus at multiple stages--by preventing the ... virus' release, which could infect other cells in the ...
... today in the journal Genome,Research that they have ... a 554-kilobase-pair genomic,segment near the centromere of the ... genes that could be implicated in,sex-associated height differences ... one of the few holes remaining in the,"finished" ...
... in comparison to the 3.2 gigabases of its human ... 14 proteins, which play different roles in promoting viral ... host’s cellular machinery—including RNA polymerases, which carry out transcription—to ... chromosomal DNA. Once the virus is integrated (now called ...
Cached Biology News:NYU Study Reveals How Brain's Immune System Fights Viral Encephalitis 2Found: Missing sequence of the human Y chromosome 2Found: Missing sequence of the human Y chromosome 3Novel Enzyme Shows Potential As An Anti-HIV Target 2Novel Enzyme Shows Potential As An Anti-HIV Target 3